L1CAM and pancreatic adenocarcinoma: [21, 23] Subsequently, other CD171-expressing tumors such as ovarian cancer, malignant melanoma and pancreatic adenocarcinoma were also targeted by anti-CD171 antibodies and indeed, some of them showed anti-tumor effects without significant side effects.